

UMC, Inc.

1770 Park Street, Suite 105, Naperville, IL 60563

630-229-6338

www.umcinc.com

info@umcinc.com

Quarterly Report

For the period ending September 30, 2025 (the "Reporting Period")

Outstanding Shares

The number of shares outstanding of our Common Stock was:

661,943,229 as of September 30 2025 (Current Reporting Period Date or More Recent Date)

656,533,246 as of December 31, 2024 (Most Recent Completed Fiscal Year End)

Shell Status

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933, Rule 12b-2 of the Exchange Act of 1934 and Rule 15c2-11 of the Exchange Act of 1934):

Yes: No:

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: No:

Change in Control

Indicate by check mark whether a Change in Control⁴ of the company has occurred during this reporting period:

Yes: No:

⁴ "Change in Control" shall mean any events resulting in:

- (i) Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;
- (ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;
- (iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or
- (iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

1) Name and address(es) of the issuer and its predecessors (if any)

In answering this item, provide the current name of the issuer and names used by predecessor entities, along with the dates of the name changes.

United Medicorp Texas, Inc. was incorporated in the State of Texas on March 13, 1989 ("UMC-Texas"). On July 10, 1989, in an exchange of stock, UMC-Texas was acquired by Gamma Resources, Inc., a publicly-owned Delaware shell corporation, which simultaneously changed its name to United Medicorp, Inc. On May 24, 2007, the Company filed "Articles of Amendment to the Articles of Incorporation of United Medicorp, Inc. whereby United Medicorp, Inc. was renamed UMC, Inc. (the "Company" or "UMC").

The Company has three wholly-owned subsidiaries. United MediCorp LLC, ("UMCL") formed July 30, 2016, and United MediCorp Acquisitions LLC ("UMCA"), formed July 22, 2020, (collectively, "SUBS"). On May 5, 2025, the Company formed UMCA SPV1, LLC, a limited liability company in the State of Illinois. UMCA SPV1, LLC is a single member Special Purpose Entity (United MediCorp Acquisitions LLC being the sole Member).

Through its SUBS, the Company is engaged in the purchase, management, and collection of charged-off accounts receivables.

Current State and Date of Incorporation or Registration: Delaware

Standing in this jurisdiction: (e.g. active, default, inactive): Active

Prior Incorporation Information for the issuer and any predecessors during the past five years:

N/A

Describe any trading suspension or halt orders issued by the SEC or FINRA concerning the issuer or its predecessors since inception:

None

List any stock split, dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

None

Address of the issuer's principal executive office:

1770 Park Street, Suite 105, Naperville, IL 60563

Address of the issuer's principal place of business:

Check if principal executive office and principal place of business are the same address:

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

No: Yes: If Yes, provide additional details below:

2) Security Information

Transfer Agent

Name: Equiniti Trust Company LLC

Phone: 718-921-8300

Email: cleibell@astfinancial.com
Address: 6201 15th Avenue, Brooklyn, NY 11219

Publicly Quoted or Traded Securities:

The goal of this section is to provide a clear understanding of the share information for its publicly quoted or traded equity securities. Use the fields below to provide the information, as applicable, for all outstanding classes of securities that are publicly traded/quoted.

Trading symbol:	<u>UMCN</u>	
Exact title and class of securities outstanding:	<u>Common Stock</u>	
CUSIP:	<u>902846104</u>	
Par or stated value:	<u>\$0.01</u>	
Total shares authorized:	<u>750,000,000</u>	as of date: <u>September 30, 2025</u>
Total shares outstanding:	<u>661,943,229</u>	as of date: <u>September 30, 2025</u>
Total number of shareholders of record:	<u>179</u>	as of date: <u>September 30, 2025</u>

Please provide the above-referenced information for all other publicly quoted or traded securities of the issuer.

Other classes of authorized or outstanding equity securities that do not have a trading symbol:

The goal of this section is to provide a clear understanding of the share information for its other classes of authorized or outstanding equity securities (e.g., preferred shares that do not have a trading symbol). Use the fields below to provide the information, as applicable, for all other authorized or outstanding equity securities.

Exact title and class of the security:	<u>Preferred Stock</u>	
Par or stated value:	<u>\$0.01</u>	
Total shares authorized:	<u>250,000,000</u>	as of date: <u>September 30, 2025</u>
Total shares outstanding:	<u>0</u>	as of date: <u>September 30, 2025</u>
Total number of shareholders of record:	<u>0</u>	as of date: <u>September 30, 2025</u>

Please provide the above-referenced information for all other classes of authorized or outstanding equity securities.

Security Description:

The goal of this section is to provide a clear understanding of the material rights and privileges of the securities issued by the company. Please provide the below information for each class of the company's equity securities, as applicable:

1. **For common equity, describe any dividend, voting and preemption rights.**

Common stock – one vote per share, no other rights or privileges.

2. **For preferred stock, describe the dividend, voting, conversion, and liquidation rights as well as redemption or sinking fund provisions.**

No designations have been completed for the authorized preferred stock. Votes, rights, or privileges of preferred shares will be determined before issuance.

3. Describe any other material rights of common or preferred stockholders.

N/A

4. Describe any material modifications to rights of holders of the company's securities that have occurred over the reporting period covered by this report.

N/A

3) Issuance History

The goal of this section is to provide disclosure with respect to each event that resulted in any changes to the total shares outstanding of any class of the issuer's securities in the past two completed fiscal years and any subsequent interim period.

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

A. Changes to the Number of Outstanding Shares for the two most recently completed fiscal years and any subsequent period.

Indicate by check mark whether there were any changes to the number of outstanding shares within the past two completed fiscal years:

No: Yes: (If yes, you must complete the table below)

Shares Outstanding <u>Opening Balance:</u> Date <u>December 31, 2022</u> Common: 199,480,092 Preferred: <u>-0-</u>			*Right-click the rows below and select "Insert" to add rows as needed.						
Date of Transaction	Transaction type (e.g., new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to. ***You must disclose the control person(s) for any entities listed.	Reason for share issuance (e.g. for cash or debt conversion) - OR- Nature of Services Provided	Restricted or Unrestricted as of this filing.	Exemption or Registration Type.
12/21/2023	New Issuance	442,752,291	Common	\$0.01	No	Stevens Financial Group, LLC - Danniel Stevens	Conversion of debt	Restricted	Rule 144
3/29/2024	New Issuance	11,565,217	Common	\$0.0115	No	Stevens Financial Group, LLC - Danniel Stevens	Conversion of debt	Restricted	Rule 144
3/29/2024	New Issuance	1,478,261	Common	\$0.0115	No	Cleston R. Lord, Jr.	Conversion of debt	Restricted	Rule 144
12/31/2024	New Issuance	1,068,032	Common	\$0.04	No	Stevens Financial	Conversion of debt	Restricted	Rule 144

						Group, LLC - Danniel Stevens			
12/31/2024	New Issuance	189,353	Common	\$0.04	No	Cleston R. Lord, Jr.	Conversion of debt	Restricted	Rule 144
3/31/2025	New Issuance	2,260,513	Common	\$0.04	No	Stevens Financial Group, LLC - Danniel Stevens	Conversion of debt	Restricted	Rule 144
6/30/2025	New Issuance	254,581	Common	\$0.04	No	Cleston R. Lord, Jr.	Conversion of debt	Restricted	Rule 144
6/30/2025	New Issuance	188,196	Common	\$0.04	No	Cleston R. Lord, Jr.	Conversion of debt	Restricted	Rule 144
6/30/2025	New Issuance	865,256	Common	\$0.04	No	Stevens Financial Group, LLC - Danniel Stevens	Conversion of debt	Restricted	Rule 144
9/30/2025	New Issuance	251,979	Common	\$0.04	No	Cleston R. Lord, Jr.	Conversion of debt	Restricted	Rule 144
9/30/2025	New Issuance	1,589,459	Common	\$0.04	No	Stevens Financial Group, LLC - Danniel Stevens	Conversion of debt	Restricted	Rule 144

Shares Outstanding on Date of This Report:

Ending Balance:

Date September 30, 2025

Common: 661,943,229

Preferred: -0-

Example: A company with a fiscal year end of December 31st 2024, in addressing this item for its Annual Report, would include any events that resulted in changes to any class of its outstanding shares from the period beginning on January 1, 2023 through December 31, 2024 pursuant to the tabular format above.

Any additional material details, including footnotes to the table are below:

B. Convertible Debt

The following is a complete list of the Company's Convertible Debt which includes all promissory notes, convertible notes, convertible debentures, or any other debt instruments convertible into a class of the issuer's equity securities. The table includes all issued or outstanding convertible debt at any time during the last complete fiscal year and any interim period between the last fiscal year end and the date of this Certification.

Check this box to confirm the Company had no Convertible Debt issued or outstanding at any point during this period.

Date of Note Issuance	Principal Amount at Issuance (\$)	Outstanding Balance (\$)	Maturity Date	Conversion Terms (e.g., pricing mechanism for determining conversion of	# Shares Converted to Date	# of Potential Shares to be Issued Upon Conversion ⁵	Name of Noteholder (entities must have individual with voting / investment control disclosed).	Reason for Issuance (e.g., Loan, Services, etc.)

⁵ The total number of shares that can be issued upon full conversion of the Outstanding Balance. The number should not factor any "blockers" or limitations on the percentage of outstanding shares that can be owned by the Noteholder at a particular time. For purposes of this calculation, please use the current market pricing (e.g. most recent closing price, bid, etc.) of the security if conversion is based on a variable market rate.

		(include accrued interest)		instrument to shares)				
1/7/2025	\$100,000	\$0	06/30/25	\$0.04 per share	2,515,097	0	Stevens Financial Group, LLC - (Danniel Stevens), and Cleston R. Lord, Jr.	Loan
5/1/25	\$50,000	\$0	06/30/25	\$0.04 per share	1,053,452		Stevens Financial Group, LLC (Danniel Stevens), and Cleston R. Lord, Jr.	Loan
5/1/25	\$50,000	\$0	09/30/25	\$0.04 per share	1,841,438		Stevens Financial Group, LLC (Danniel Stevens), and Cleston R. Lord, Jr.	Loan
Total Outstanding Balance:		\$0		Total Shares:	5,409,987			

Any additional material details, including footnotes to the table are below:

4) Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations. Ensure that these descriptions are updated on the Company's Profile on www.OTCMarkets.com.

A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

The Company provides accounts receivable management and "after collection" services to healthcare providers. The Company engages proprietary and purchased software to provide these services to its customers; primarily independent healthcare providers. In addition, the Company also offers traditional collection services through its partners.

Management believes it has developed a line of services addressing healthcare providers' collection needs. The Company has partnered with other companies that provide enhanced software, computer hardware and maintenance, and other valuable services specifically designed for healthcare providers. Management believes these efforts will produce a system that provides the Company's customers with enhanced cash flow.

The Company offers two primary services: Bad Debt Collection Services and a Debt Purchasing Program.

Bad Debt Collection Services: This service involves the third-party collection of accounts written off as bad debt.

Debt Purchasing Program: Healthcare providers participating in the Debt Purchasing Program agree to transfer ownership of accounts, or a portfolio of accounts, to the Company for an agreed-upon price significantly less than the face amount of the account, or portfolio of accounts. UMC and its affiliates assume all risks and receive all collections from such purchases.

During 2024, under its debt purchasing program, the Company entered into three contracts to acquire four account portfolios. During the year ending December 31, 2024, United MediCorp Acquisitions LLC generated \$3,961 in revenue from collections. During first quarter of 2025, the Company acquired one (1) additional portfolio. During the nine months ending September 30, 2025, United MediCorp Acquisitions LLC generated \$25,291 in revenue from collections. The Company has not begun generating revenue from its other potential revenue streams.

B. Please list any subsidiaries, parents, or affiliated companies.

United MediCorp LLC, United MediCorp Acquisitions LLC, and UMC SPV1, LLC

C. Describe the issuers' principal products or services.

The Company offers two primary services: Bad Debt Collection Services and its Debt Purchasing Program.

5) Issuer's Facilities

The goal of this section is to provide investors with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer and the extent in which the facilities are utilized.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer. Describe the location of office space, data centers, principal plants, and other property of the issuer and describe the condition of the properties. Specify if the assets, properties, or facilities are owned or leased and the terms of their leases. If the issuer does not have complete ownership or control of the property, describe the limitations on the ownership.

The Company's corporate offices and operations are located in 1,500 square feet of leased office space in Naperville, Illinois. This space is provided rent-free from a related party. Management believes that the facilities are well-located and are in good condition. The Company's future facilities requirements will depend upon the success of its business, and management believes that there is adequate office space available should its space requirements increase.

6) All Officers, Directors, and Control Persons of the Company

Using the table below, please provide information, as of the period end date of this report, regarding all officers and directors of the company, or any person that performs a similar function, regardless of the number of shares they own.

In addition, list all individuals or entities controlling 5% or more of any class of the issuer's securities.

If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity. Include Company Insiders who own any outstanding units or shares of any class of any equity security of the issuer.

The goal of this section is to provide investors with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial owners.

Individual Name (First, Last) or Entity Name (Include names of control person(s) if a corporate entity)	Position/Company Affiliation (ex: CEO, 5% Control person)	City and State (Include Country if outside U.S.)	Number of Shares Owned (List common, preferred, warrants and options separately)	Class of Shares Owned	Percentage of Class of Shares Owned (undiluted)
Stevens Financial Group, Danniell Stevens	Chairman & CEO	Aurora, Illinois	579,126,144	Common	87.5%
Cleston R. Lord, Jr.	Corporate Secretary	Bronx, New York	8,510,391	Common	1.3%
Benjamin Willingham	Investor	Naperville, Illinois	45,830,000	Common	6.9%
Douglas Sawyer	President, United MediCorp Acquisitions LLC	Loganville, Georgia	0	Common	N/A

Confirm that the information in this table matches your public company profile on www.OTCMarkets.com. If any updates are needed to your public company profile, log in to www.OTCIQ.com to update your company profile.

7) Legal/Disciplinary History

A. Identify and provide a brief explanation as to whether any of the persons or entities listed above in Section 6 have, in the past 10 years:

1. Been the subject of an indictment or conviction in a criminal proceeding or plea agreement or named as a defendant in a pending criminal proceeding (excluding minor traffic violations);

None

2. Been the subject of the entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, financial- or investment-related, insurance or banking activities;

None

3. Been the subject of a finding, disciplinary order or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, a state securities regulator of a violation of federal or state securities or commodities law, or a foreign regulatory body or court, which finding or judgment has not been reversed, suspended, or vacated;

None

4. Named as a defendant or a respondent in a regulatory complaint or proceeding that could result in a "yes" answer to part 3 above; or

None

5. Been the subject of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

None

6. Been the subject of a U.S Postal Service false representation order, or a temporary restraining order, or preliminary injunction with respect to conduct alleged to have violated the false representation statute that applies to U.S mail.

None

B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party to or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

None

8) Third Party Service Providers

Provide the name, address, telephone number and email address of each of the following outside providers. You may add additional space as needed.

Confirm that the information in this table matches your public company profile on www.OTCMarkets.com. If any updates are needed to your public company profile, update your company profile.

Securities Counsel

Name: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

Accountant or Auditor

Name: Cicely A Parada-Obreque, CPA
Firm: Integrität Audit Accounting & Advisory, LLC
Address 1: 1825 NW Corporate Blvd., Suite 110
Address 2: Boca Raton, FL 33431
Phone: (561) 210-7284
Email: cicely@integritatcpa.com

Investor Relations

Name: _____
Firm: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

All other means of Investor Communication:

X (Twitter): _____
Discord: _____
LinkedIn: _____
Facebook: _____
[Other]: _____

Other Service Providers

Provide the name of any other service provider(s) that **that assisted, advised, prepared, or provided information with respect to this disclosure statement.** This includes counsel, broker-dealer(s), advisor(s), consultant(s) or any entity/individual that provided assistance or services to the issuer during the reporting period.

Name: Vanessa J. Schoenthaler, Partner
Firm: Saul Ewing LLP
Nature of Services: Securities Attorneys
Address 1: 1270 Avenue of the Americas, Ste. 2800
Address 2: New York, New York 10020
Phone: (212) 980-7208
Email: vanessa.schoenthaler@saul.com

Name: Ann Leong, CPA
Firm: KCL Accounting Services, LLC
Nature of Services: Accounting & Bookkeeping services
Address 1: 1255 S. State Street
Address 2: Chicago, IL 60605
Phone: (312) 437-0645
Email: annleo38@yahoo.com

9) Disclosure & Financial Information

A. This Disclosure Statement was prepared by (name of individual):

Name: Rachel Boulds
Title: Outsourced CPA
Relationship to Issuer: Service Provider

B. The following financial statements were prepared in accordance with:

- IFRS
 U.S. GAAP

C. The following financial statements were prepared by (name of individual):

Name: Rachel Boulds
Title: Outsourced CPA
Relationship to Issuer: Service Provider

Describe the qualifications of the person or persons who prepared the financial statements:⁶ Licensed CPA in the State of Utah.

Provide the following qualifying financial statements:

- Audit letter, if audited;
- Balance Sheet;
- Statement of Income;
- Statement of Cash Flows;
- Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)
- Financial Notes

Financial Statement Requirements:

- Financial statements must be published together with this disclosure statement as one document.
- Financial statements must be "machine readable". Do not publish images/scans of financial statements.
- Financial statements must be presented with comparative financials against the prior FYE or period, as applicable.
- Financial statements must be prepared in accordance with U.S. GAAP or International Financial Reporting Standards (IFRS) but are not required to be audited.

10) Issuer Certification

Principal Executive Officer:

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

The certifications shall follow the format below:

I, Danniel Stevens certify that:

1. I have reviewed this Disclosure Statement for UMC, Inc;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and

⁶ The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS and by persons with sufficient financial skills.

3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

November 11, 2025

/s/ Danniell Stevens

Principal Financial Officer:

I, Danniell Stevens certify that:

1. I have reviewed this Disclosure Statement for UMC, Inc;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

November 11, 2025

/s/ Danniell Stevens

UMC, INC.

**CONSOLIDATED FINANCIAL STATEMENTS
FOR THE NINE MONTHS ENDED
SEPTEMBER 30, 2025**

UMC, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS

	September 30, 2025	December 31, 2024
ASSETS		
(Unaudited)		
Current Assets:		
Cash and cash equivalents	\$ 5,731	\$ 17,348
Receivables from collection agency	412	801
Prepaid expense	281	780
Total current assets	<u>6,424</u>	<u>18,929</u>
Non Current Assets:		
Collection receivable - collection portfolios, net	44,207	20,746
Total non current assets	<u>44,207</u>	<u>20,746</u>
Total assets	<u>\$ 50,631</u>	<u>\$ 39,675</u>
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)		
Current Liabilities:		
Accounts payable and accrued liabilities	\$ 19,033	\$ 20,207
Total current liabilities	<u>19,033</u>	<u>20,207</u>
Total liabilities	<u>19,033</u>	<u>20,207</u>
Stockholders' equity (deficit):		
Preferred stock, \$0.01 par value; 250,000,000 shares authorized; no shares issued and outstanding,	—	—
Common stock, \$0.01 par value; 750,000,000 and 200,000,000 shares authorized, respectively; 661,943,229 and 656,533,246, shares issued and outstanding, respectively	6,619,432	6,565,332
Additional paid in capital	19,323,236	19,143,495
Accumulated deficit	(25,911,070)	(25,689,359)
Total stockholders' equity (deficit)	<u>31,598</u>	<u>19,468</u>
Total liabilities and stockholders' equity (deficit)	<u>\$ 50,631</u>	<u>\$ 39,675</u>

The accompanying notes are an integral part of these unaudited consolidated financial statements.

UMC, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)

	For the Three Months Ended September 30,		For the Nine Months Ended September 30,	
	2025	2024	2025	2024
Revenues	\$ 7,785	\$ 1,243	\$ 25,291	\$ 2,616
Cost of revenue				
Collection costs	2,824	—	9,223	—
Total cost of revenue	2,824	—	9,223	—
Gross margin	4,961	1,243	16,068	2,616
Operating Expenses:				
General and administrative	95,003	37,906	233,575	123,932
Total operating expenses	95,003	37,906	233,575	123,932
Loss from operations	(90,042)	(36,663)	(217,504)	(121,316)
Other Expenses:				
Interest expense (income)	(727)	142	(1,976)	(384)
Write off of collection receivable	—	—	(2,231)	—
Total other expenses	(727)	142	(4,207)	(384)
Net Loss	\$ (90,769)	\$ (36,521)	\$ (221,711)	\$ (121,700)
Net loss per share	\$ (0.00)	\$ (0.00)	\$ (0.00)	\$ (0.00)
Weighted average shares outstanding, basic and diluted	660,101,792	655,275,861	658,489,337	651,086,715

The accompanying notes are an integral part of these unaudited consolidated financial statements.

UMC, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024
(Unaudited)

	Common Stock		Additional Paid in Capital	Accumulated Deficit	Total Stockholders' Equity (Deficit)
	Shares	Amount			
Balance, December 31, 2024	656,533,246	\$ 6,565,332	\$ 19,143,495	\$ (25,689,359)	\$ 19,468
Common stock issued for conversion of debt – related party	2,260,513	22,605	67,815	—	90,420
Contributed rent – related party	—	—	5,814	—	5,814
Net loss	—	—	—	(65,801)	(65,801)
Balance, March 31, 2025	658,793,759	6,587,937	19,217,124	(25,755,160)	49,901
common stock issued for conversion of debt – related party	1,308,032	13,081	39,241	—	52,322
Contributed rent – related party	—	—	5,814	—	5,814
Net loss	—	—	—	(65,141)	(65,141)
Balance, June 30, 2025	660,101,791	6,601,018	19,262,179	(25,820,301)	42,896
common stock issued for conversion of debt – related party	1,841,438	18,414	55,243	—	73,657
Contributed rent – related party	—	—	5,814	—	5,814
Net loss	—	—	—	(90,769)	(90,769)
Balance, September 30, 2025	<u>661,943,229</u>	<u>\$ 6,619,432</u>	<u>\$ 19,323,236</u>	<u>\$ (25,911,070)</u>	<u>\$ 31,598</u>

	Common Stock		Additional Paid in Capital	Accumulated Deficit	Total Stockholders' Equity (Deficit)
	Shares	Amount			
Balance, December 31, 2023	642,232,383	\$ 6,422,324	\$ 19,062,952	\$ (25,513,322)	\$ (28,046)
Common stock issued for conversion of debt – related party	13,043,478	130,435	19,565	—	150,000
Contributed rent – related party	—	—	5,814	—	5,814
Net loss	—	—	—	(54,142)	(54,142)
Balance, March 31, 2024	655,275,861	6,552,759	19,088,331	(25,567,464)	73,626
Contributed rent – related party	—	—	5,814	—	5,814
Net loss	—	—	—	(31,037)	(31,037)
Balance, June 30, 2024	655,275,861	6,552,759	19,094,145	(25,598,501)	48,403
Contributed rent – related party	—	—	5,814	—	5,814
Net loss	—	—	—	(36,521)	(36,521)
Balance, September 30, 2024	<u>655,275,861</u>	<u>\$ 6,552,759</u>	<u>\$ 19,099,959</u>	<u>\$ (25,635,022)</u>	<u>\$ 17,696</u>

The accompanying notes are an integral part of these unaudited consolidated financial statements.

UMC, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)

	For the Nine Months Ended September 30,	
	2025	2024
Cash flows from operating activities:		
Net loss	\$ (221,711)	\$ (121,700)
Adjustments to reconcile net loss to net cash used by operating activities:		
Owner's contributed lease expense	17,442	17,442
Amortization of allowance for credit losses	(24,375)	(2,615)
Collection costs settled from receivable balance	9,223	—
Write off collection receivable	2,231	—
Changes in assets and liabilities:		
Prepaid and deposits	499	5,112
Accounts payable and accrued liabilities	(1,173)	(7,169)
Due to related party	—	160
Receivables from collection agency	389	—
Accrued interest	1,125	—
Net cash used in operating activities	<u>(216,350)</u>	<u>(108,770)</u>
Cash flows from investing activities:		
Purchase of collection portfolios	(26,165)	(20,987)
Proceeds from collection receivables	15,623	2,743
Net cash used in investing activities	<u>(10,541)</u>	<u>(18,244)</u>
Cash flows from financing activities:		
Proceeds received from convertible notes payable - related party	215,274	117,900
Net cash provided by financing activities	<u>215,274</u>	<u>117,900</u>
Net change in cash	(11,617)	(9,114)
Cash at beginning period	17,348	11,975
Cash at end of period	<u>\$ 5,731</u>	<u>\$ 2,861</u>
Supplemental disclosure of cash flow information:		
Cash paid for interest	<u>\$ —</u>	<u>\$ 558</u>
Cash paid for taxes	<u>\$ —</u>	<u>\$ —</u>
Supplemental disclosure of non-cash activity:		
Common stock issued for conversion of amounts due to related parties	<u>\$ 216,400</u>	<u>\$ 150,000</u>

The accompanying notes are an integral part of these unaudited consolidated financial statements.

UMC, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2025
(Unaudited)

NOTE 1 — NATURE OF OPERATIONS

United Medicorp Texas, Inc. was incorporated in the State of Texas on March 13, 1989 ("UMC-Texas"). On July 10, 1989, in an exchange of stock, UMC-Texas was acquired by Gamma Resources, Inc., a publicly-owned Delaware shell corporation, which simultaneously changed its name to United Medicorp, Inc. On May 24, 2007, the Company filed "Articles of Amendment to the Articles of Incorporation of United Medicorp Inc., whereby United Medicorp Inc. was renamed UMC, Inc. (the "Company", or "UMC").

The Company has three wholly-owned subsidiaries. United MediCorp LLC ("UMCL") was formed on July 30, 2016, and United MediCorp Acquisitions LLC ("UMCA") was formed on July 22, 2020 (collectively, "SUBS"). Through its SUBS, the Company is engaged in the purchase, management, and collection of charged-off accounts receivables. The Company's fiscal year-end is December 31st.

On May 5, 2025, the Company formed UMCA SPV1, LLC, a limited liability company in the State of Illinois. UMCA SPV1, LLC is a single member Special Purpose Entity (United MediCorp Acquisitions LLC being the sole Member).

NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying unaudited consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America ("U.S. GAAP") as found in the Accounting Standards Codification ("ASC") and the Accounting Standards Update ("ASU") of the Financial Accounting Standards Board ("FASB") and are expressed in US Dollars. Significant accounting policies applicable to the Company are summarized as follows:

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Principles of Consolidation

The accompanying unaudited consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, UMCL and UMCA. All significant intercompany transactions and balances have been eliminated in consolidation.

Cash and Cash Equivalents

The Company considers all highly liquid investments with an original maturity date of three months or less at the time of purchase to be cash equivalents. The Company has cash of \$5,731 and \$17,348 as of September 30, 2025 and December 31, 2024, respectively.

Allowance for Credit Losses

The Company estimates its allowance for credit losses using the Current Expected Credit Loss (CECL) model under ASC 326. The CECL model requires recognition of expected credit losses over the contractual life of financial assets held at the reporting date, considering the nature of debt, industry expectations, current conditions, and reasonable and supportable forecasts.

Financial assets subject to CECL include trade receivables. The Company groups financial assets based on shared risk characteristics and evaluates them collectively. The allowance is measured using a combination of historical activity, industry expectations, adjusted

for current economic trends and forward-looking factors such as industry outlook and macroeconomic indicators (e.g., unemployment rate, GDP).

Under CECL, the carrying amount of a financial asset (net of the allowance for credit losses) represents the amount the Company expects to collect. This means that when the CECL estimate is appropriately recorded, the net reported balance of financial assets reflects management's best estimate of collectible cash flows, based on available and supportable information.

Management reviews the adequacy of the allowance at each reporting period and updates estimates as appropriate. Changes in estimates are recorded in the income statement as a component of credit loss expense.

Related Party Transactions

Under ASC 850 "Related Party Transactions" an entity or person is considered to be a "related party" if it has control, significant influence, or is a key member of management personnel or affiliate. A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties. The Company, in accordance with ASC 850 presents disclosures about related party transactions and outstanding balances with related parties. In accordance with SAB Topic 5.T, "Accounting for Expenses or Liabilities Paid by Principal Stockholder(s)", if a principal stockholder settles an obligation on behalf of the entity, it should be reflected as an expense in the company's financial statements with a corresponding credit to contributed (paid-in) capital, unless the stockholder's action is caused by a relationship or obligation completely unrelated to their position as a stockholder or such action clearly does not benefit the company. Related parties advance funds to sustain operations and a related party provides premises for the Company's operations. The market value of premises provided is material and represents an obligation or expense that benefits the Company; therefore, the Company is required to incur this expense at its market value.

Fair Value of Financial Instruments

The fair value is the exit price that would be received upon selling an asset or the amount required to transfer a liability in an orderly transaction between market participants. As such, the fair value of a financial instrument is a market-based measurement that should be determined based on the assumptions market participants would use to price an asset or a liability.

A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value:

- Level 1: Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.
- Level 2: Observable inputs that reflect quoted prices for identical assets or liabilities in markets that are not active; quoted prices for similar assets or liabilities in active markets; inputs other than quoted prices that are observable for the assets or liabilities; or inputs that are derived principally from or corroborated by observable market data by correlation or other means.
- Level 3: Unobservable inputs reflecting our own assumptions incorporated in valuation techniques used to determine fair value. These assumptions are required to be consistent with market participants' assumptions that are reasonably available.

On September 30, 2025, there are no instruments requiring fair value hierarchy disclosure. The carrying amount of the Company's financial assets and liabilities, such as cash, prepaid expenses, accounts payable, and accrued expenses approximate their fair value because of the short maturity of those instruments.

Derivative Liabilities – Conversion Features

The Company evaluates whether embedded conversion features in its financial instruments meet the criteria for separate accounting under ASC 815, "Derivatives and Hedging." If the conversion feature is not clearly and closely related to the host debt instrument and does not meet the scope exception for equity classification, it is bifurcated and accounted for as a derivative liability.

Derivative liabilities are initially measured at fair value on the issuance date and remeasured at each reporting period, with changes in fair value recognized in earnings. The fair value of these liabilities is determined by using appropriate valuation models, such as the Black-Scholes or binomial option pricing models, incorporating inputs such as the Company's stock price, volatility, risk-free interest

rate, and the terms of the conversion feature. There was no convertible debt outstanding on September 30, 2025 and December 31, 2024, and therefore no derivative considerations were required or value determined.

Leases

The Company has a month-to-month lease arrangement exempted from ASC 842 lease recognition due to it being short-term. The lease is for 1,500 square feet of office space, with a reasonable market value, from a principal stockholder for no consideration. In accordance with SAB Topic 5.T, if a principal stockholder settles an obligation on behalf of the Company, which benefits the Company, it should be reflected as an expense in the Company's financial statements with a corresponding credit to contributed (paid-in) capital, at its market value. Management considers this arrangement to be a short-term obligation to provide office space satisfied by the stockholder on a month-to-month basis; it therefore incurs the value of the lease as an expense and records a contribution of capital and is exempt from recognizing the lease under ASC 842. There is currently no long term intention to maintain this lease due to the business' growth projections; within a year or less the premises may not suit the Company's needs.

Equity

In accordance with ASC 505 "Equity," the Company considers an equity instrument to be any contract that evidences a residual interest in the assets of an entity after deducting all its liabilities. The Company's common shares are classified as equity instruments. Incremental costs directly attributable to the issuance of new shares are recognized in equity as a reduction from the gross proceeds received from the issued shares. Share capital is reported on the balance sheet and statement of changes in shareholders' deficit.

Basic and Diluted Loss Per Share

Under ASC 260 "Earnings Per Share," the Company presents basic and diluted earnings (loss) per share ("EPS") amounts on the face of the statements of operations. Basic EPS is computed by dividing income (loss) available to common stockholders (the numerator) by the weighted-average number of common shares outstanding (the denominator) during the period. Shares issued and reacquired during the period are weighted by the portion of the period during which they were outstanding. The computation of diluted EPS is similar to the computation of basic EPS except that the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued. There were no potentially dilutive securities outstanding at September 30, 2025 and 2024. Additionally, diluted amounts are not presented when the effect of the computations is anti-dilutive due to the losses incurred. Accordingly, there is no difference in the amounts presented for basic and diluted loss per share.

Revenue Recognition

The Company recognizes revenue under ASC 606, "Revenue from Contracts with Customers," and in accordance with ASC 326, "Financial Instruments-Credit Losses". The core principle of the new revenue standard is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The following five steps are applied to achieve that core principle:

- Step 1: Identify the contract with the customer.
- Step 2: Identify the performance obligations in the contract.
- Step 3: Determine the transaction price.
- Step 4: Allocate the transaction price to the performance obligations in the contract.
- Step 5: Recognize revenue when the Company satisfies a performance obligation.

The contract with the customer is determined as the acquisition agreement with the Seller to pursue the collection of patient balances for the fee of whatever amount is collected.

The performance obligation is the service of pursuing collections of the Seller's patient balances.

The transaction price (sales price the Company is entitled to receive for services) is a range and is determinable upon collections realized. The potential maximum collections would be the present value of the account balance acquired, as demonstrated in the actual account balance list obtained from the Seller, and the Buyer's estimated minimum collections would be the consideration paid for the account. The agreement does not guarantee any collections.

There is a single performance obligation, and therefore, the allocation to performance obligations would not apply to the nature of revenue.

In consideration that the agreement does not guarantee any collections, revenue would only be recognized after the cost for the account is recuperated, and collections exceed the cost the buyer paid for the account.

When determining the transaction price, the Company also considers the effects of all the following:

- Variable consideration.
- Constraining estimates of variable consideration.
- The existence of a significant financing component in the contract.
- Noncash consideration.
- Consideration payable to a customer.

There is no determinable variable consideration, significant financing component, non-cash consideration, or consideration payable to customers.

Collection Services to Independent Healthcare Providers

The Company generates revenues from collection services for balances owed to independent healthcare providers. UMCA acquires patient healthcare account balances with deteriorated credit quality. The accounts acquired by UMCA consist of unpaid service balances and do not include interest or fees previously assessed. The accounts are sold and transferred to UMCA without recourse and representation or warranties of any kind. UMC assumes all risks of collections. The seller agrees to sell, convey, transfer, and assign to UMCA customer accounts for a fee. The contracts executed in 2024 and 2025 indicate the fee or purchase consideration ranges from 1.0% to 4.25% of the balance owed by customers, a significant discount to the face amount. These accounts are trade receivables, financial assets with no effective interest rates, discounts, or premiums. The seller may recall any account subsequent to the acquisition date that it or a prior holder of the account determines may be subject to litigation, threatened litigation, adversarial administration, or that it otherwise determines is in its interest to recall to preserve or defend its rights or interests. If such notice is delivered to UMCA, UMCA would immediately cease all communications with accountholders and collection activities, have its tradeline removed from any credit reporting agencies, and update the tradeline status to "Recalled by Seller". If there is any regulatory adjustment to a balance owed, the seller of these accounts will update UMCA to adjust accordingly. Within five (5) business days of UMCA obtaining notice from the seller of an account recall or an agreed repurchase of account(s) by the seller, UMCA will transfer all necessary records and rights back to the seller, and the seller is to pay the repurchase price. From the start of account acquisitions in 2024 to September 30, 2025, there has been no such recall.

In accordance with ASC 326, the acquired customer accounts are determined to be Purchased Financial Assets with Credit Deterioration (PCD). ASC requires special accounting for the acquisition of debt with deteriorated credit quality. At initial recognition, the debt instrument is booked at its present value as "Collections Receivable," any debt discount or premium is recorded, the cash paid to acquire the instrument is credited, and the remaining present value is allocated to "Allowance for Credit Losses." At subsequent measurement, the principal would be reduced when payments are received for each related debt. Collections more than the consideration paid for each customer's account would result in the amortization of "Allowance for Credit Losses" and the recognition of "Collection Revenues."

Additionally, the Company engages third-party debt collection agencies to recover outstanding balances on its behalf, pursuant to an agreed-upon fee structure. The agencies report to the Company collections by the 5th day of the subsequent month. In accordance with ASC 310 - Receivables and ASC 326 - Financial Instruments - Credit Losses, at each period end the full collections received by the agency is applied against the collections receivable reducing its balance, the amount retained by the agency for their services is incurred as a cost of services, accounts receivable is increased for the net amount the agency is to remit to the Company. Similarly, as when collected directly, the portion of total collections by agencies that is more than the cost paid for the account is amortized from "Allowance for Credit Losses" and recognized as revenues.

Operating Segments

Operating segments are defined as components of an entity for which discrete financial information is available and regularly reviewed by the Chief Operating Decision Maker ("CODM") or decision-maker group in deciding how to allocate resources to an individual

segment and in assessing performance. Our chief operating decision-making group is composed of the Chief Executive Officer. The Company has one operating segment generating revenue as of September 30, 2025 and 2024.

Recently Issued Accounting Pronouncements

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures, which requires disclosure of incremental segment information on an annual and interim basis, primarily disclosure of significant segment expense categories and amounts for each reportable segment. The new standard is effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company adopted ASU 2023-07 in the annual financial statements for the year ended December 31, 2024, and for interim periods beginning in 2025. The Company adopted this ASU, effective for the year ended December 31, 2024. The adoption had no impact on the Company's financial statements.

The Company periodically reviews new accounting standards that are issued. Although some of these accounting standards may apply to the Company, the Company has not identified any new standards that it believes merit further discussion or change to adopted policies, and the Company expects that none will have a significant impact on its financial statements.

Income Taxes

The Company follows the liability method of accounting for income taxes. Under this method, deferred income tax assets and liabilities are recognized for the estimated tax consequences of differences between the financial statement carrying values and their respective income tax basis (temporary differences). The effect on deferred income tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

FASB Accounting Standards Codification Topic 740, Income Taxes ("ASC 740"), clarifies the accounting for uncertainty in income taxes recognized in the financial statements. ASC 740 provides that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits of the position. Income tax positions must meet a more-likely-than-not-recognition threshold to be recognized. ASC 740 also provides guidance on measurement, derecognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. We have determined that the Company does not have uncertain tax positions on its tax returns for the years 2024, and prior. Based on the evaluation of the 2025 transactions and events, the Company does not believe it has any material uncertain tax positions that require measurement.

The IRS requires all domestic corporations in existence for any part of the tax year to file an income tax return, whether or not they have taxable income. The Company incurred a loss for the fiscal years ended December 31, 2024, and 2023, and has filed tax returns for both years. The Company has not received any notifications from the IRS. Reported tax benefits and valuation allowances are the Company's best estimate of its tax positions and have not been reviewed by the taxing authority.

The Company's policy is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had no accrual for interest or penalties on its consolidated balance sheets at September 30, 2025, or December 31, 2024, and have not recognized interest and/or penalties in the consolidated statement of operations for the periods ended September 30, 2025, or the year ended December 31, 2024.

The Company is subject to taxation in the United States and the State of Delaware. The Company's federal and applicable state income tax returns for the past three years remain subject to examination by the respective tax authorities.

NOTE 3 — GOING CONCERN

The accompanying unaudited consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. On a consolidated basis, the Company has incurred significant operating losses since its inception. For the nine months ended September 30, 2025, and 2024, the Company incurred net losses of \$221,711 and \$121,700, respectively. On September 30, 2025, and December 31, 2024, the Company has an accumulated deficit of \$25,911,070 and \$25,689,358, negative working capital of \$12,609 and \$1,277, and cash balances of \$5,731 and \$17,348, respectively.

The Company does not expect that existing operational cash flows will be sufficient to fund anticipated operations, which raises substantial doubt about the Company's ability to continue as a going concern for a period of twelve months from the issuance date of this report. Therefore, the Company will need to raise additional funds and is currently exploring alternative financing sources. Historically, the Company has raised capital through notes and convertible loans from a related party as an interim measure to finance working capital and will continue to do so. The Company plans to raise additional capital through the sale of common stock or other securities, as well as short-term loans.

The ability to recognize revenue and cash receipts is contingent upon, but not limited to, the acceptable performance of the services delivered. If the Company cannot raise additional capital and/or close on some of its revenue-producing opportunities in the near term, the carrying value of its assets may be materially impacted. The unaudited consolidated financial statements do not include any adjustments related to the recovery and classification of asset-carrying amounts or the amount and classification of liabilities that might result should the Company be unable to continue as a going concern.

Management intends to finance operating costs over the next twelve months with existing cash on hand and loans from its directors. Management is also working to secure new financing. The Company's ability to obtain the new funding is not known at this time.

NOTE 4 — CONCENTRATION AND CREDIT RISK

Financial instruments that potentially subject the Company to credit risk consist principally of cash and collection receivables. Cash is maintained with a creditworthy major financial institution in the USA. The Company maintains cash in a bank account insured up to \$250,000 by the Federal Deposit Insurance Corporation ("FDIC"). At September 30, 2025 and December 31, 2024, no cash balances were held in excess of federally insured limits. The risk of non collections of the collection receivable is uniquely high due to the nature of charged off patient accounts acquired, therefore these balances are reported net of a significant allowance for potential non collections, see Note 6.

Currently, the Company's primary source of capital to sustain operations comes from its CEO (a principal shareholder), a related entity controlled by the CEO, and the Company's Corporate Secretary.

On September 30, 2025, amounts owed to one vendor exceeded 83.91% of total accounts payable and accrued liabilities represented 45.4% of the total.

On December 31, 2024, the amounts owed to three vendors exceeded 10% of total accounts payable and accrued liabilities.

NOTE 5 — PREPAID EXPENSES

On September 30, 2025, the Company had \$281 in prepaid insurance expense for its 2025 coverage. On December 31, 2024, the Company had \$780 in prepaid insurance expense for its 2025 coverage.

NOTE 6 — COLLECTION RECEIVABLES

On January 4, 2024, UMCA entered into an accounts receivable purchase agreement with an unrelated party to purchase 498 charged-off patient accounts. The total value of the accounts receivable purchased was \$297,490. The purchase price of these accounts receivable was \$12,643, or 4.25% of the receivable value.

On January 15, 2024, UMCA entered into an accounts receivable purchase agreement with an unrelated party to purchase 116 charged-off patient accounts. The total value of the accounts receivable purchased was \$64,462. The purchase price of these accounts receivable was \$2,740, or 4.25% of the receivable value.

On March 5, 2024, UMCA entered into an accounts receivable purchase agreement with an unrelated party to purchase 196 charged-off patient accounts. The total value of the accounts receivable purchased was \$131,850. The purchase price of these accounts receivable was \$5,604, or 4.25% of the receivable value.

On January 23, 2025, UMCA entered into a sales and purchase agreement with an unrelated party to purchase 2,597 charged-off patient accounts. The total value of accounts receivable purchased was \$2,083,592. The purchase price of these accounts was \$26,164 or 1.36% of the receivable value.

As of September 30, 2025, total Collections Receivable amounted to \$2,491,462, with an Allowance for Credit Losses of \$2,447,255, resulting in a net realizable value of \$44,207. As of December 31, 2024, total Collections Receivable amounted to \$489,601, with an Allowance for Credit Losses of \$468,855, resulting in a net realizable value of \$20,746. The Company evaluates account holders' responsiveness at each reporting period to determine whether adjustments to the Allowance for Credit Losses are necessary. For the nine months ending September 30, 2025, the Company earned \$25,291 in collection revenues, reflecting the commencement of collections on these accounts and recovered \$2,851 related to previous acquisition costs. Collection receivable activity is as follows:

Description	September 30, 2025	December 31, 2024
Collection receivable beginning balance	\$ 489,601	\$ —
Collection accounts purchased	2,083,592	493,802
Collections	(15,324)	(2,969)
Receivables from collection agency	(412)	(801)
Collection costs for agency	(9,223)	(431)
Accounts written off	(56,772)	—
Collection Receivable ending balance	\$ 2,491,462	\$ 489,601
Allowance for doubtful accounts	(2,447,255)	(468,855)
Collection Receivable, net	\$ 44,207	\$ 20,746

NOTE 7 — ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

Accounts payable and accrued liabilities were comprised of the following:

	September 30, 2025	December 31, 2024
Trade accounts payable	\$ 10,387	\$ 14,948
Credit cards payable	8,646	5,259
Total accounts payable and accrued liabilities	\$ 19,033	\$ 20,207

NOTE 8 — RELATED PARTY TRANSACTIONS

On January 1, 2024, the Company entered into a rent-free, month-to-month lease arrangement with Stevens Financial Group, L.L.C. to occupy 1,500 square feet of office space in Naperville, Illinois. The property potentially rents for \$1,938 per month. Therefore, the Company incurred a lease expense and contributed capital of \$17,442 and \$17,442 during the nine months ended September 30, 2025 and 2024, respectively.

On January 7, 2025, the Company issued a Convertible Promissory Note to Stevens Financial Group, L.L.C. (“SFG”), and Cleston R. Lord, Jr. for an amount up to \$100,000. The note bears interest at 4.71%, matures in 90 days, and is convertible into shares of common stock at \$0.04 per share. During the nine months ending September 30, 2025, SFG and Mr. Lord loaned the Company \$187,974 and \$27,500, respectively.

Effective February 21, 2025, the Company approved the Sixth Amendment to the Consulting Agreement between UMC, Inc. and Stevens & Associates Consulting, LLC, which extends the term to December 31, 2030.

On March 31, 2025, SFG converted \$90,000 of principal and \$420 of interest into 2,260,513 common shares. As the amount converted exceeded the liability at March 31, 2025, \$11,000 of an Other Receivable-Related Party was disclosed on the balance sheet and has been offset by loans made to the Company during the April 1st through April 29th period.

On May 1, 2025, the Company issued a Convertible Promissory Note to Stevens Financial Group, LLC (“SFG”), and Cleston R. Lord, Jr., for an amount up to \$20,000. The note bears interest at 4.71%, matures in 60 days, and is convertible into shares of common stock at \$0.04 per share.

Effective May 15, 2025, the Company amended the existing note dated May 1, 2025, to a rolling convertible promissory note to which Stevens Financial Group, L.L.C. and Cleston R. Lord, Jr. will make available to the Company up to \$50,000 per calendar quarter to be

used for general and working capital. At each quarter-end of calendar year 2025, any outstanding principal and accrued interest will be convertible into common stock of the Company at \$0.04 per share.

On June 30, 2025, SFG converted \$34,500 and \$111 of principal and interest under the May 1st Revolving Convertible Note, respectively, into 865,256 common shares.

On June 30, 2025, Mr. Lord converted \$7,500 and \$28 of principal and interest, respectively, into 188,196 common shares.

On June 30, 2025, Mr. Lord converted \$10,000 and \$183 of principal and interest, respectively, into 254,581 common shares.

On September 30, 2025, SFG converted \$63,274 and \$304 of principal and interest under the May 1st Revolving Convertible Note, respectively, into 1,589,459 common shares.

On September 30, 2025, Mr. Lord converted \$10,000 and \$79 of principal and interest, respectively, into 251,979 common shares.

As of September 30, 2025, there are no amounts owed to SFG or Mr. Lord.

NOTE 9 – PREFERRED STOCK

On December 26, 2023, the Company filed, amended, and restated its Certificate of Incorporation with the Secretary of State of the State of Delaware, which created 250,000,000 shares of preferred stock, par value of \$0.01 per share. No shares have been issued as of September 30, 2025.

The Company has 250,000,000 preferred shares authorized at a par value of \$0.01 per share. As of September 30, 2025, and December 31, 2024, no preferred shares were issued and outstanding.

NOTE 10 — COMMON STOCK

On December 26, 2023, the Company filed, amended, and restated its Certificate of Incorporation with the Secretary of State of the State of Delaware, increasing the authorized number of common shares to 750,000,000 from 200,000,000. The par value remains at \$0.01 per share.

As of September 30, 2025 and December 31, 2024, there were 661,943,229 and 656,533,246 common shares issued and outstanding, respectively.

See Note 8 for issuance of shares to related parties.

NOTE 11 — COMMITMENTS AND CONTINGENCIES

From time to time, the Company may be a defendant in pending or threatened legal proceedings arising in the normal course of its business. Management is not aware of any pending, threatened, or asserted claims.

On February 14, 2023, the Company entered into a Buyer Consultant Agreement (“Agreement”) between United MediCorp Acquisitions LLC and an unrelated entity (“the Consultant”) whereby the Company was to receive consulting services in the area of finding potential sellers of debt portfolios, that it may be interested in purchasing. The Agreement has an initial one-year term that automatically renews for another year unless either party provides the other party written notice of termination, which would be effective only on the current term’s expiration. As compensation for the services performed, the Company will pay the Consultant a fee of 5% of the gross funded amount for all charged-off portfolios purchased and 2% of the gross funded amount for all performing portfolios purchased. As of September 30, 2025, one portfolio was acquired under this agreement. No portfolio was acquired under this agreement during the fiscal year ended December 31, 2024.. During the nine months ended September 30, 2025 and 2024, the consultant fee expense was \$1,308 and \$0 respectively.

A Certificate of Authority to transact business is required in every state where the Company transacts business but has no physical presence within that particular state.

On March 15, 2024, UMCA was issued a Certificate of Authority to transact business in Georgia. UMCA plans to conduct collection services in the state. On August 10, 2024, UMCA was issued Certificates of Authority to transact business in Alabama, Iowa, and Kentucky. On August 13, 2024, UMCA was issued a Certificate of Authority to transact business in Delaware, Indiana, New Jersey, South Carolina, and Vermont. On August 16, 2024, UMCA was issued a Certificate of Authority to transact business in Kansas. On August 19, 2024, UMCA was issued a Certificate of Authority to transact business in Florida.

On October 24, 2024, UMCA was issued a Certificate of Authority to transact business in Ohio. On October 29, 2024, UMCA was issued a Certificate of Authority to transact business in Louisiana.

On December 1, 2024, UMCA was issued a Certificate of Authority to transact business in New Hampshire. On December 2, 2024, UMCA was issued a Certificate of Authority to transact business in Rhode Island. On December 8, 2024, UMCA was issued a Certificate of Authority to transact business in West Virginia. On December 16, 2024, UMCA was issued Certificates of Authority to transact business in the District of Columbia, Mississippi, and Tennessee. On December 17, 2024, UMCA was issued a Certificate of Authority to transact business in North Carolina. On December 20, 2024, UMCA was issued a Certificate of Authority to transact business in the Commonwealth of Pennsylvania. On December 27, 2024, UMCA was issued Certificates of Authority to transact business in Connecticut and Maine. On December 29, 2024, UMCA was issued a Certificate of Authority to transact business in Missouri. On December 30, 2024, UMCA was issued Certificates of Authority to transact business in Maryland and Oklahoma.

On November 4, 2024, the Company hired Douglas L. Sawyer as President of United MediCorp Acquisitions LLC.

On November 4, 2024, the Company, through its wholly-owned subsidiary United MediCorp Acquisitions LLC, entered into a Collection Services Agreement with a California-based collection agency (hereafter referred to as "the Agency") to provide third party services. Under the terms of this agreement, the Agency is engaged to provide comprehensive debt collection services for UMCA for a fee of 35.0% of the gross amount collected from debtors. The Agency is responsible for managing the entire collection process, which includes initial contact, negotiation, settlement, and, if necessary, the coordination and management of legal proceedings. The Agreement is effective from November 4, 2024, and will remain in force unless terminated by either party with thirty (30) days' written notice. Upon termination, the Agency is required to return all accounts to UMCA, except for those accounts with payment activity, within sixty (60) days prior to termination. Additionally, the Agency is obligated to provide UMCA with monthly reports by the 5th of each calendar month, detailing the gross and net amounts collected in the prior month. The Agency is to remit funds collected between the 1st and 15th of each month by wire transfer on the 20th and funds collected between the 16th and the end of the month by the 5th of the following month. Collection cost incurred under this agreement for the nine months ended September 30, 2025 and 2024 was \$7,231 and \$431, respectively.

On June 16, 2025, UMCA and CWR LLC entered into an agreement whereby Karen White, a consultant, will provide strategic, operational, and compliance advisory services and serve as acting operations officer to the Company.

On July 3, 2025, UMCA was issued a Certificate of Authority to transact business in Virginia.

On July 7, 2025, the Company, through its wholly-owned subsidiary United MediCorp Acquisitions LLC, entered into a Collection Services Agreement with a Syosset, New York-based collection agency (hereafter referred to as "Agency2") to provide third party services. Under the terms of this agreement, Agency2 is engaged to provide comprehensive debt collection services for UMCA for a percentage of the gross amount collected from debtors. Agency2 is responsible for managing the entire collection process, which includes initial contact, negotiation, settlement, and, if necessary, the coordination and management of legal proceedings. The Agreement is effective from July 7, 2025, and will remain in force unless terminated by either party with thirty (30) days' written notice. Upon termination, Agency2 is required to return all accounts to UMCA, except for those accounts with payment activity, within sixty (60) days prior to termination. Additionally, Agency2 is obligated to provide UMCA with monthly reports by the 5th of each calendar month, detailing the gross and net amounts collected in the prior month. Agency2 will deduct its fee and remit the remainder to UMCA, by each Friday including payments received through the Tuesday of the same week, by close of business each Friday. No collection costs were incurred under this agreement for the nine months ended September 30, 2025 and fiscal 2024.

On July 7, 2025, the Company, through its wholly-owned subsidiary United MediCorp Acquisitions LLC, entered into a Collection Services Agreement with a Pittsburg, Pennsylvania-based collection agency (hereafter referred to as "Agency3") to provide third party services. Under the terms of this agreement, Agency3 is engaged to provide comprehensive debt collection services for UMCA for a percentage of the gross amount collected from debtors. Agency3 is responsible for managing the entire collection process, which includes initial contact, negotiation, settlement, and, if necessary, the coordination and management of legal proceedings. The

Agreement is effective from July 7, 2025, and will remain in force unless terminated by either party with thirty (30) days' written notice. Upon termination, Agency3 is required to return all accounts to UMCA, except for those accounts with payment activity, within sixty (60) days prior to termination. Additionally, Agency3 is obligated to provide UMCA with monthly reports by the 5th of each calendar month, detailing the gross and net amounts collected in the prior month. Agency3 will deduct its fee and remit the remainder to UMCA, by each Friday including payments received through the Tuesday of the same week, by close of business each Friday. Collection costs incurred under this agreement for the nine months ended September 30, 2025 and 2024 was \$1,992 and \$0 respectively.

On July 7, 2025, the Company, through its wholly-owned subsidiary United MediCorp Acquisitions LLC, entered into a Collection Services Agreement with a Houston, Texas-based collection agency (hereafter referred to as "Agency4") to provide third party services. Under the terms of this agreement, Agency4 is engaged to provide comprehensive debt collection services for UMCA for a percentage of the gross amount collected from debtors. Agency4 is responsible for managing the entire collection process, which includes initial contact, negotiation, settlement, and, if necessary, the coordination and management of legal proceedings. The Agreement is effective from July 7, 2025, and will remain in force unless terminated by either party with thirty (30) days' written notice. Upon termination, Agency4 is required to return all accounts to UMCA, except for those accounts with payment activity, within sixty (60) days prior to termination. Additionally, Agency4 is obligated to provide UMCA with monthly reports by the 5th of each calendar month, detailing the gross and net amounts collected in the prior month. Agency4 will deduct its fee and remit the remainder to UMCA, by each Friday including payments received through the Tuesday of the same week, by close of business each Friday. No collection costs were incurred under this agreement for the nine months ended September 30, 2025 and fiscal 2024.

On July 7, 2025, the Company, through its wholly-owned subsidiary United MediCorp Acquisitions LLC, entered into a Collection Services Agreement with a Minnetonka, Minnesota-based collection agency (hereafter referred to as "Agency5") to provide third party services. Under the terms of this agreement, Agency5 is engaged to provide comprehensive debt collection services for UMCA for a percentage of the gross amount collected from debtors. Agency5 is responsible for managing the entire collection process, which includes initial contact, negotiation, settlement, and, if necessary, the coordination and management of legal proceedings. The Agreement is effective from July 7, 2025, and will remain in force unless terminated by either party with thirty (30) days' written notice. Upon termination, Agency5 is required to return all accounts to UMCA, except for those accounts with payment activity, within sixty (60) days prior to termination. Additionally, Agency5 is obligated to provide UMCA with monthly reports by the 5th of each calendar month, detailing the gross and net amounts collected in the prior month. Agency5 will deduct its fee and remit the remainder to UMCA, by each Friday including payments received through the Tuesday of the same week, by close of business each Friday. No collection costs were incurred under this agreement for the nine months ended September 30, 2025 and fiscal 2024.

On July 7, 2025, the Company, through its wholly-owned subsidiary United MediCorp Acquisitions LLC, entered into a Collection Services Agreement with a Hi Nella, New Jersey-based collection agency (hereafter referred to as "Agency6") to provide third party services. Under the terms of this agreement, Agency6 is engaged to provide comprehensive debt collection services for UMCA for a percentage of the gross amount collected from debtors. Agency6 is responsible for managing the entire collection process, which includes initial contact, negotiation, settlement, and, if necessary, the coordination and management of legal proceedings. The Agreement is effective from July 7, 2025, and will remain in force unless terminated by either party with thirty (30) days' written notice. Upon termination, Agency6 is required to return all accounts to UMCA, except for those accounts with payment activity, within sixty (60) days prior to termination. Additionally, Agency6 is obligated to provide UMCA with monthly reports by the 5th of each calendar month, detailing the gross and net amounts collected in the prior month. Agency6 will deduct its fee and remit the remainder to UMCA, by each Friday including payments received through the Tuesday of the same week, by close of business each Friday. No collection costs were incurred under this agreement for the nine months ended September 30, 2025 and fiscal 2024.

During July 2025, the Company entered into an engagement with an independent service auditor to perform a SOC 2 Type II examination covering its systems related to security and confidentiality for the period August 1, 2024 through July 31, 2025. The engagement was completed in September 2025. The engagement was undertaken as part of the Company's ongoing compliance and risk management initiatives and is unrelated to the audit of the Company's financial statements.

On August 8, 2025, the Company, through its wholly-owned subsidiary United MediCorp Acquisitions LLC, entered into a Master Services Agreement with a cloud based Collection Software service provider to be deployed across its receivable's operations. The term of the agreement continues until all orders have either expired or have been terminated. The platform's advanced analytics and workflow automation are expected to increase recovery rates and reduce cycle times while offering robust audit trails and compliance tools which align with UMCA's regulatory obligations and internal governance standards.

See Note 6 – Collection Receivables

See Note 8 – for details of Related Party Transactions.

Note 12 — INCOME TAX

For the nine months ended September 30, 2025 and fiscal year ending December 31, 2024, there was no provision for income taxes and deferred tax assets have been entirely offset by valuation allowances.

As of September 30, 2025 and December 31, 2024, the Company had net operating loss carry forwards of approximately \$10,126,524 and \$9,950,487, respectively. The carry forwards expire through the year 2044. The Company's net operating loss carry forwards may be subject to annual limitations, which could reduce or defer the utilization of the losses as a result of an ownership change as defined in Section 382 of the Internal Revenue Code.

The tax computations are as follows:

	<u>September 30, 2025</u>	<u>December 31, 2024</u>
Net losses before taxes	\$ (221,711)	\$ (176,037)
Adjustments to arrive at taxable loss:		
Permanent differences:	—	—
Temporary differences:	—	—
Taxable loss	<u>\$ (221,711)</u>	<u>\$ (176,037)</u>
Current Year Taxable loss	\$ (221,711)	\$ (176,037)
NOL carried forward prior year (tax return)	\$ (10,126,524)	\$ (9,950,487)
NOL carried forward at period end	<u>\$ (10,348,235)</u>	<u>\$ (10,126,524)</u>
Deferred Tax Asset - Federal Rate (21%)	\$ 2,173,129	\$ 2,126,570
Deferred Tax Asset - State Rate (8.7%)	\$ 900,296	\$ 881,008
Total Deferred Tax Asset	<u>\$ 3,073,426</u>	<u>\$ 3,007,578</u>
Valuation Allowance	<u>\$ (3,073,426)</u>	<u>\$ (3,007,578)</u>
Deferred tax per books	<u>\$ —</u>	<u>\$ —</u>

NOTE 13 — SUBSEQUENT EVENTS

Management has evaluated subsequent events and transactions occurring through November 10, 2025, the date these unaudited consolidated financial statements were issued and determined that the following material subsequent events are required subsequent disclosures.

On October 05, 2025, UMCA was issued a Certificate of Authority to transact business in South Dakota. On October 06, 2025, UMCA was issued a Certificate of Authority to transact business in Montana. On October 10, 2025, UMCA was issued a Certificate of Authority to transact business in North Dakota. On October 13, 2025, UMCA was issued a Certificate of Authority to transact business in Arkansas. On October 15, 2025, UMCA was issued a Certificate of Authority to transact business in Colorado. On October 25, 2025, UMCA was issued a Certificate of Authority to transact business in New Mexico. On October 29, 2025, UMCA was issued a Certificate of Authority to transact business in Nebraska.

On November 02, 2025, UMCA was issued a Certificate of Authority to transact business in Minnesota. On November 06, 2025, UMCA was issued a Certificate of Authority to transact business in Wyoming. On November 09, 2025, UMCA was issued a Certificate of Authority to transact business in Wisconsin. On November 10, 2025, UMCA was issued a Certificate of Authority to transact business in Michigan.

On November 03, 2025, the Company, through its wholly-owned subsidiary United MediCorp Acquisitions LLC, entered into a technology services agreement with a third-party provider to implement machine learning-based models for account and portfolio

segmentation and prioritization. The agreement supports the Company's strategic objective to enhance operational efficiency and data-driven decision-making across its receivables management functions. Management believes that the integration of machine learning technology will contribute to improved portfolio performance, reduced operational costs, and enhanced compliance oversight. The Company will continue to evaluate the effectiveness of this solution and its alignment with long-term strategic goals.

As of November 10, 2025, UMCA has applications pending for Certificates of Authority in California, Hawaii, Idaho, New York, and Washington.

On November 10, 2025, UMCA was issued a Certificate of Authority to transact a business in the state of Michigan.

The consolidated financial statements do not include any adjustments that may result from these conditions. Management is not aware of any other significant events that have occurred after the balance sheet date that would require adjustments to or disclosure in the consolidated financial statements.